|
|
Volumn 88, Issue 1, 2002, Pages 173-175
|
|
A rebuttal: Vitamin K antagonists and cancer survival (multiple letters)
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICOAGULANT AGENT;
ANTINEOPLASTIC AGENT;
ANTIVITAMIN K;
CISPLATIN;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
ETOPOSIDE;
LOMUSTINE;
METHOTREXATE;
VINBLASTINE;
VINDESINE;
WARFARIN;
VITAMIN K GROUP;
ANTINEOPLASTIC ACTIVITY;
BLOOD CLOTTING;
CANCER;
CANCER GROWTH;
CANCER MORTALITY;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL TRIAL;
DEEP VEIN THROMBOSIS;
DRUG EFFECT;
DRUG RESPONSE;
EVIDENCE BASED MEDICINE;
FEASIBILITY STUDY;
HUMAN;
KIDNEY CARCINOMA;
LETTER;
LONG TERM CARE;
LUNG SMALL CELL CANCER;
MELANOMA;
META ANALYSIS;
METABOLIC ACTIVATION;
OUTCOMES RESEARCH;
PANCREAS CARCINOMA;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
PROBABILITY;
PROSPECTIVE STUDY;
PROSTATE CANCER;
PROTHROMBIN TIME;
SIDE EFFECT;
STATISTICAL SIGNIFICANCE;
DRUG ANTAGONISM;
MORTALITY;
NEOPLASM;
NOTE;
SMALL CELL CARCINOMA;
SURVIVAL RATE;
ANTICOAGULANTS;
CARCINOMA, SMALL CELL;
HUMANS;
NEOPLASMS;
SURVIVAL RATE;
VITAMIN K;
WARFARIN;
|
|
EID: 0013378936
PISSN: 03406245
EISSN: None
Source Type: Journal
DOI: 10.1055/s-0037-1613181 Document Type: Letter |
|
Times cited : (7)
|
|
References (0)
|
